TFEB overexpression in excitatory neurons ameliorates amyloid‐β pathology via coordinated enhancement of autophagy‐lysosome and mitochondrial function

Lei Wang, Li‐peng Jing, Hai‐chao Chen, Yue‐zhang Ma, Jia‐xin Cao, Yi‐shu Zhang, Yong‐gang Wang, Yu‐hong Jing, Zhen‐chang Zhang
Journal of Pathology · Wiley · 2026-11-17 · DOI: 10.1002/path.70153

Abstract

Abstract The intraneuronal accumulation of amyloid‐β (Aβ) is an early pathogenic event in Alzheimer's disease (AD), initiating a pathological cascade that includes synaptic dysfunction, metabolic deficits, and eventual neuronal loss. Transcription factor EB (TFEB), a master regulator of the autophagy‐lysosomal pathway (ALP) and mitochondrial homeostasis, represents a promising therapeutic target. However, its efficacy and mechanisms when specifically activated in neurons during the prodromal stage remain unclear. Here, we used an adeno‐associated virus (AAV) under the control of the CaMKIIα promoter to achieve excitatory neuron‐specific TFEB overexpression in the hippocampal CA1 region of 2 months‐old 5×FAD mice. This intervention significantly reduced soluble Aβ levels at 3 months and attenuated amyloid plaque burden, dystrophic neurite formation, and glial activation at 6 months, accompanied by substantial improvements in spatial learning and memory. Mechanistically, transcriptomic and functional analyses revealed that TFEB not only enhanced autophagic flux and lysosomal biogenesis but also promoted the expression of key mitochondrial genes and improved mitochondrial function. In APP695swe‐N2a cells, TFEB overexpression increased levels of LC3B‐II and LAMP1, enhanced mitochondrial activity and biogenesis (via PGC‐1α upregulation), and effectively reduced intracellular Aβ accumulation. Our findings demonstrate that targeted TFEB overexpression in excitatory neurons during early AD pathogenesis initiates a protective cascade by co‐activating autophagy‐lysosomal clearance and mitochondrial pathways, thereby reducing Aβ accumulation and mitigating downstream pathology. This study highlights the potential of neuron‐specific TFEB activation as a cell‐type‐specific therapeutic approach for early AD intervention. © 2026 The Pathological Society of Great Britain and Ireland.

Read at publisher →

Similar articles